OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. Each product in OncoGenex's oncology pipeline has a distinct mechanism of action and represents a unique opportunity for cancer drug development.

Salmedix, a leading developer of oncology drugs with a commercial focus on the treatment of hematologic malignancies, was acquired by Cephalon (Nasdaq: CEPH).

NOVADAQ® Technologies, Inc., a leading developer of medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular, opthalmic and neurologic diseases and conditions, completed its initial public offering in June of 2005 (NDQ).